896 related articles for article (PubMed ID: 33155503)
1. Ketamine: A tale of two enantiomers.
Jelen LA; Young AH; Stone JM
J Psychopharmacol; 2021 Feb; 35(2):109-123. PubMed ID: 33155503
[TBL] [Abstract][Full Text] [Related]
2. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.
Yang C; Yang J; Luo A; Hashimoto K
Transl Psychiatry; 2019 Nov; 9(1):280. PubMed ID: 31699965
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
Hashimoto K
Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
[TBL] [Abstract][Full Text] [Related]
4. Ketamine for depression.
Jelen LA; Stone JM
Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
[TBL] [Abstract][Full Text] [Related]
5. A historical review of antidepressant effects of ketamine and its enantiomers.
Wei Y; Chang L; Hashimoto K
Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of ketamine action as an antidepressant.
Zanos P; Gould TD
Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
Wei Y; Chang L; Hashimoto K
Mol Psychiatry; 2022 Jan; 27(1):559-573. PubMed ID: 33963284
[TBL] [Abstract][Full Text] [Related]
8. AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine.
Yang C; Kobayashi S; Nakao K; Dong C; Han M; Qu Y; Ren Q; Zhang JC; Ma M; Toki H; Yamaguchi JI; Chaki S; Shirayama Y; Nakazawa K; Manabe T; Hashimoto K
Biol Psychiatry; 2018 Oct; 84(8):591-600. PubMed ID: 29945718
[TBL] [Abstract][Full Text] [Related]
9. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
10. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K
Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
[TBL] [Abstract][Full Text] [Related]
11. Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
Zhang JC; Yao W; Hashimoto K
Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629
[TBL] [Abstract][Full Text] [Related]
12. R (-)-methoxetamine exerts rapid and sustained antidepressant effects and fewer behavioral side effects relative to S (+)-methoxetamine.
Botanas CJ; Perez Custodio RJ; Kim HJ; de la Pena JB; Sayson LV; Ortiz DM; Kim M; Lee HJ; Acharya S; Kim KM; Lee CJ; Ryu JH; Lee YS; Cheong JH
Neuropharmacology; 2021 Aug; 193():108619. PubMed ID: 34023336
[TBL] [Abstract][Full Text] [Related]
13. Differentially regulated targets in the fast-acting antidepressant effect of (R)-ketamine: A systems biology approach.
Scotton E; Casa PL; de Abreu FP; de Avila E Silva S; Wilges RLB; Rossetto MV; Géa LP; Rosa AR; Colombo R
Pharmacol Biochem Behav; 2023 Feb; 223():173523. PubMed ID: 36731751
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C
Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380
[TBL] [Abstract][Full Text] [Related]
15. TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats.
Hara H; Suzuki A; Kunugi A; Tajima Y; Yamada R; Kimura H
Pharmacol Biochem Behav; 2021 Dec; 211():173289. PubMed ID: 34655652
[TBL] [Abstract][Full Text] [Related]
16. Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers.
Scotton E; Antqueviezc B; Vasconcelos MF; Dalpiaz G; Paul Géa L; Ferraz Goularte J; Colombo R; Ribeiro Rosa A
Biochem Pharmacol; 2022 Apr; 198():114963. PubMed ID: 35182519
[TBL] [Abstract][Full Text] [Related]
17. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.
Aleksandrova LR; Phillips AG; Wang YT
J Psychiatry Neurosci; 2017 Jun; 42(4):222-229. PubMed ID: 28234212
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of ketamine and its metabolites as antidepressants.
Hess EM; Riggs LM; Michaelides M; Gould TD
Biochem Pharmacol; 2022 Mar; 197():114892. PubMed ID: 34968492
[TBL] [Abstract][Full Text] [Related]
20. The antidepressant actions of ketamine and its enantiomers.
Johnston JN; Henter ID; Zarate CA
Pharmacol Ther; 2023 Jun; 246():108431. PubMed ID: 37146727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
